At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction
In Brief
A Phase 4 clinical trial evaluating Ticagrelor and Clopidogrel for Myocardial Infarction. Completed, enrolled 60 participants across 2 sites in 2 countries.
Detailed Summary
Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors are essential for platelet activation. Antagonists against the P2Y12 receptor, which are established in secondary prevention of myocardial infarction, have unexplained anti-inflammatory effects. A novel P2Y12 receptor antagonist ticagrelor reduced infection-related mortality compared to clopidogrel, previous standard treatment for patients with myocardial infarction. Activated platelets release pro-inflammatory and procoagulant platelet extracellular vesicles. The investigators assume that decrease in infection-related mortality in patients treated with ticagrelor may be explained by greater inhibition of the release of platelet vesicles by ticagrelor, compared to clopidogrel. This study is expected to identify an additional mechanism of action of ticagrelor, which might contribute to the observed clinical benefits in patients treated with ticagrelor.
Study Details
Timeline
Interventions
Comparison of ticagrelor with another antiplatelet drug (clopidogrel)
Comparison of clopidogrel with another antiplatelet drug (ticagrelor)